Bayer HealthCare opens its API development and manufacturing
capabilities to external customers

Wuppertal – Bayer HealthCare AG, a subgroup of Bayer AG with over 34,000 employees and 8.9 billion € sales in 2003, is known as one of the world’s leading innovative companies in the health care industry. In the Pharma- and Chemical Park in Wuppertal, Bayer HealthCare (BHC) has assembled its key biotechnology and chemical development functions along with cGMP manufacturing facilities for pharmaceuticals.

At the CPhI 2004, the company announces its decision to expand its contract development/manufacturing activities in Wuppertal/Germany. One primary focus are chemical development services, where BHC offers an integrated package of process R&D, analytical development, regulatory affairs and consulting modules to suit the individual customer’s requirements.
According to Dr. Rolf Angerbauer, BHC’s head of chemical development, “Companies with chemical development needs will profit from a partnership with Bayer HealthCare in a number of ways: They can tap into our long-standing experience in the successful development of drug candidates from preclinical to market. Our well-proven development strategy will enable our customers to rapidly enter clinical trials. They can rely on the quality of the product we deliver and the high level of dedication of our skilled personnel. After all, pharma is our business.”
Facilities include a modern pilot plant with seven independent compartments designed specifically for the scale-up and Small-Scale GMP manufacturing of APIs. Its high level of containment and cleanliness classes make this facility particularly suitable for the production of Highly Actives and Injectibles. Chemical and biological products with registered manufacturing processes requiring larger volumes up to 8 m3 and 80 m3, respectively, can be produced to Bayer quality standards in plants of BHC’s API production unit. The site is FDA-approved, inspected by customers and local authorities and meets the requirements of ISO 14001. A wide variety of established and innovative technologies is available.
Optimally complementing the contract services for small molecules, the biotechnology capabilities of Bayer HealthCare’s multi-purpose pilot/production plants span from fermentation and biotransformations to the purification of biomolecules such as recombinant proteins, secondary metabolites and biocatalysts. The plant is registered for the use of recombinant microorganisms up to the 40 m3 scale and has available a large flame-proof downstream processing area.
For companies looking for a site to start up or relocate their facilities, the Pharma- and Chemical Park in Wuppertal offers tailored pharma-specific prerequisites including grounds, laboratory and office space, access to FDA-approved production plants and associated infrastructure.
Bayer HealthCare has thus positioned itself as a strong, versatile and experienced partner for the pharmaceutical and biotech industries.

Further information on the “Pharma und Chemiepark Wuppertal” can be obtained by visiting our website:
www.pharma-und-chemiepark.de

November 2004

Please address all enquiries to:

Herbert Stillings
Phone: +49 (0)202 / 36-75 87
E-Mail: herbert.stillings@bayerhealthcare.com

Forward-looking statements
This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

top